Urotensin II promotes hypertrophy of cardiac myocytes via mitogen-activated protein kinases

Molecular Endocrinology

Volumn 18, Issue 9, 2004, Pages 2344-2354

  Onan, Döne ^a,b   Pipolo, Luisa ^a   Yang, Eunice ^a   Hannan, Ross D ^a,c   Thomas, Walter G ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ADENOVIRUS VECTOR; CALCIUM; EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE C; STRESS ACTIVATED PROTEIN KINASE; TYROSINE; UROTENSIN II;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; NEWBORN; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; SARCOMERE; TRANSACTIVATION;

ADENOVIRIDAE; ANIMALS; CARDIOMEGALY; CELL ENLARGEMENT; CELLS, CULTURED; CLONING, MOLECULAR; GENETIC VECTORS; GLYCOPROTEINS; MITOGEN-ACTIVATED PROTEIN KINASES; MYOCYTES, CARDIAC; RATS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, G-PROTEIN-COUPLED; TRANS-ACTIVATION (GENETICS); UP-REGULATION; UROTENSINS;

ADENOVIRIDAE; ANIMALIA;

EID: 4544246563     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2003-0309     Document Type: Article

References (59)

1. Ames RS, Sarau HM, Chambers JK, Willette RN, Aiyar NV, Romanic AM, Louden CS, Foley JJ, Sauermelch CF, Coatney RW, Ao Z, Disa J, Holmes SD, Stadel JM, Martin JD, Liu WS, Glover GI, Wilson S, McNulty DE, Ellis CE, Elshourbagy NA, Shabon U, Trill JJ, Hay DW, Douglas SA, et al 1999 Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 401:282-286
2. Coulouarn Y, Lihrmann I, Jegou S, Anovar Y, Tostivint H, Beauvillain JC, Conlon JM, Bern HA, Vaudry H 1998 Cloning of the cDNA encoding the urotensin II precursor in frog and human reveals intense expression of the urotensin II gene in motoneurons of the spinal cord. Proc Natl Acad Sci USA 95:15803-15808
3. Liu Q, Pong SS, Zeng Z, Zhang Q, Howard AD, Williams Jr DL, Davidoff M, Wang R, Austin CP, McDonald TP, Bai C, George SR, Evans JF, Caskey CT 1999 Identification of urotensin II as the endogenous ligand for the orphan G-protein-coupled receptor GPR14. Biochem Biophys Res Commun 266:174-178
4. Nothacker HP, Wang Z, McNeill AM, Saito Y, Mertens S, O'Dowd B, Duckles SP, Civelli O 1999 Identification of the natural ligand of an orphan G-protein-coupled receptor involved in the regulation of vasoconstriction. Nat Cell Biol 1:383-385
5. Saetrum Opgaard O, Nothacker H, Ehlert FJ, Krause DN 2000 Human urotensin II mediates vasoconstriction via an increase in inositol phosphates. Eur J Pharmacol 406:265-271
6. Zhu YZ, Wang ZJ, Zhu YC, Zhang L, Oakley RM, Chung CW, Lim KW, Lee HS, Ozoux ML, Linz W, Bohm M, Kostenis E 2004 Urotensin II causes fatal circulatory collapse in anesthesized monkeys in vivo: a "vasoconstrictor" with a unique hemodynamic profile. Am J Physiol 286:H830-H836
7. Maguire JJ, Davenport AP 2002 Is urotensin-II the new endothelin? Br J Pharmacol 137:579-588
8. Silvestre RA, Rodriguez-Gallardo J, Egido EM, Marco J 2001 Inhibition of insulin release by urotensin II - a study on the perfused rat pancreas. Horm Metab Res 33:379-381
9. Totsune K, Takahashi K, Arihara Z, Sone M, Ito S, Murakami O 2003 Increased plasma urotensin II levels in patients with diabetes mellitus. Clin Sci (Colch) 104:1-5
10. Totsune K, Takahashi K, Arihara Z, Sone M, Satoh F, Ito S, Kimura Y, Sasano H, Murakami O 2001 Role of urotensin II in patients on dialysis. Lancet 358:810-811
11. Matsushita M, Shichiri M, Imai T, Iwashina M, Tanaka H, Takasu N, Hirata Y 2001 Co-expression of urotensin II and its receptor (GPR14) in human cardiovascular and renal tissues. J Hypertens 19:2185-2190
12. Sauzeau V, Le Mellionnec E, Bertoglio J, Scalbert E, Pacaud P, Loirand G 2001 Human urotensin II-induced contraction and arterial smooth muscle cell proliferation are mediated by RhoA and Rho-kinase. Circ Res 88:1102-1104
13. Watanabe T, Pakala R, Katagiri T, Benedict CR 2001 Synergistic effect of urotensin II with serotonin on vascular smooth muscle cell proliferation. J Hypertens 19:2191-2196
14. Watanabe T, Pakala R, Katagiri T, Benedict CR 2001 Synergistic effect of urotensin II with mildly oxidized LDL on DNA synthesis in vascular smooth muscle cells. Circulation 104:16-18
15. Takahashi K, Totsune K, Murakami O, Shibahara S 2001 Expression of urotensin II and urotensin II receptor mRNAs in various human tumor cell lines and secretion of urotensin II-like immunoreactivity by SW-13 adrenocortical carcinoma cells. Peptides 22:1175-1179
16. Takahashi K, Totsune K, Murakami O, Arihara Z, Noshiro T, Hayashi Y, Shibahara S 2003 Expression of urotensin II and its receptor in adrenal tumors and stimulation of proliferation of cultured tumor cells by urotensin II. Peptides 24:301-306
17. Shenouda A, Douglas SA, Ohlstein EH, Giaid A 2002 Localization of urotensin-II immunoreactivity in normal human kidneys and renal carcinoma. J Histochem Cytochem 50:885-889
18. Douglas SA, Tayara L, Ohlstein EH, Halawa N, Giaid A 2002 Congestive heart failure and expression of myocardial urotensin II. Lancet 359:1990-1997
19. Zhou P, Wu SY, Yu CF, Wang H, Tang CS, Lin L, Yuan WJ 2003 [Effects of urotensin II on isolated rat hearts under normal perfusion and ischemia reperfusion]. Sheng Li Xue Bao 55:442-448
20. Zhang Y, Li J, Cao J, et al 2002 Effect of chronic hypoxia on contents of urotensin II and its functional receptors in rat myocardium. Heart Vessels 16:64-68
21. Tzanidis A, Hannan RD, Thomas WG, Onan D, Autelitano DJ, See F, Kelly DJ, Gilbert RE, Krum H 2003 Direct actions of urotensin II on the heart. Implications for cardiac fibrosis and hypertrophy. Circ Res 93:246-253
22. Russell FD, Molenaar P, O'Brien DM 2001 Cardiostimulant effects of urotensin-II in human heart in vitro. Br J Pharmacol 132:5-9
23. He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, Vogelstein B 1998 A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 95:2509-2514
24. Hannan RD, Luyken J, Rothblum LI 1996 Regulation of ribosomal DNA transcription during contraction-induced hypertrophy of neonatal cardiomyocytes. J Biol Chem 271:3213-3220
25. Thomas WG, Brandenburger Y, Autelitano DJ, Pham T, Qian H, Hannan RD 2002 Adenoviral-directed expression of the type 1A angiotensin receptor promotes cardiomyocyte hypertrophy via transactivation of the epidermal growth factor receptor. Circ Res 90:135-142
26. Chien KR, Knowlton KU, Zhu H, Chien S 1991 Regulation of cardiac gene expression during myocardial growth and hypertrophy: molecular studies of an adaptive physiologic response. FASEB J 5:3037-3046
27. Smith NJ, Chan H-W, Osborne JE, Thomas WG, Hannan RD, Hijacking of EGF receptors by angiotensin II: new possibilities for understanding and treating cardiac hypertrophy. Cell Mol Life Sci, in press
28. Sugden PH, Clerk A 1998 Cellular mechanisms of cardiac hypertrophy. J Mol Med 76:725-746
29. Itoh H, McMaster D, Lederis K 1988 Functional receptors for fish neuropeptide urotensin II in major rat arteries. Eur J Pharmacol 149:61-66
30. Zou Y, Nagai R, Yamazaki T 2001 Urotensin II induces hypertrophic responses in cultured cardiomyocytes from neonatal rats. FEBS Lett 508:57-60
31. Hannan RD, Stefanovsky V, Taylor L, Moss T, Rothblum LI 1996 Overexpression of the transcription factor UBF1 is sufficient to increase ribosomal DNA transcription in neonatal cardiomyocytes: implications for cardiac hypertrophy. Proc Natl Acad Sci USA 93:8750-8755
32. Yue TL, Gu JL, Wang C, Reith AD, Lee JC, Mirabile RC, Kreutz R, Wang Y, Maleeff B, Parsons AA, Ohlstein EH 2000 Extracellular signal-regulated kinase plays an essential role in hypertrophic agonists, endothelin-1 and phenylephrine-induced cardiomyocyte hypertrophy. J Biol Chem 275:37895-37901
33. Post GR, Goldstein D, Thuerauf DJ, Glembotski CC, Brown JH 1996 Dissociation of p44 and p42 mitogen-activated protein kinase activation from receptor-induced hypertrophy in neonatal rat ventricular myocytes. J Biol Chem 271:8452-8457
34. Esposito G, Prasad SV, Rapacciuolo A, Mao L, Koch WJ, Rockman HA 2001 Cardiac overexpression of a G(q) inhibitor blocks induction of extracellular signal-regulated kinase and c-Jun NH(2)-terminal kinase activity in in vivo pressure overload. Circulation 103:1453-1458
35. Ng DC, Long CS, Bogoyevitch MA 2001 A role for the extracellular signal-regulated kinase and p38 mitogen-activated protein kinases in interleukin-1 β-stimulated delayed signal transducer and activator of transcription 3 activation, atrial natriuretic factor expression, and cardiac myocyte morphology. J Biol Chem 276:29490-29498
36. Sugden PH, Clerk A 1998 "Stress-responsive" mitogen-activated protein kinases (c-Jun N-terminal kinases and p38 mitogen-activated protein kinases) in the myocardium. Circ Res 83:345-352
37. Zechner D, Thuerauf DJ, Hanford DS, McDonough PM, Glembotski CC 1997 A role for the p38 mitogen-activated protein kinase pathway in myocardial cell growth, sarcomeric organization, and cardiac-specific gene expression. J Cell Biol 139:115-127
38. Bogoyevitch MA 2000 Signalling via stress-activated mitogen-activated protein kinases in the cardiovascular system. Cardiovasc Res 45:826-842
39. Eguchi S, Dempsey PJ, Frank GD, Motley ED, Inagami T 2001 Activation of MAPKs by angiotensin II in vascular smooth muscle cells. Metalloprotease- dependent EGF receptor activation is required for activation of ERK and p38 MAPK but not for JNK. J Biol Chem 276:7957-7962
40. Shah BH, Catt KJ 2003 A central role of EGF receptor transactivation in angiotensin II-induced cardiac hypertrophy. Trends Pharmacol Sci 24:239-244
41. Kanda Y, Mizuno K, Kuroki Y, Watanabe Y 2001 Thrombin-induced p38 mitogen-activated protein kinase activation is mediated by epidermal growth factor receptor transactivation pathway. Br J Pharmacol 132:1657-1664
42. Clerk A, Sugden PH 1999 Activation of protein kinase cascades in the heart by hypertrophic G protein-coupled receptor agonists. Am J Cardiol 83:64H-69H
43. Asakura M, Kitakaze M, Takashima S, Liao Y, Ishikura F, Yoshinaka T, Ohmoto H, Node K; Yoshino K, Ishiguro H, Asanuma H, Sanada S, Matsumura Y, Takeda H, Beppu S, Tada M, Hori M, Higashiyama S 2002 Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy. Nat Med 8:35-40
44. Zhao YY, Sawyer DR, Baliga RR, Opel DJ, Han X, Marchionni MA, Kelly RA 1998 Neuregulins promote survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes. J Biol Chem 273:10261-10269
45. Prenzel N, Fischer OM, Streit S, Hart S, Ullrich A 2001 The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr Relat Cancer 8:11-31
46. Milano CA, Dolber PC, Rockman HA, Bond RA, Venable ME, Allen LF, Lefkowitz RJ 1994 Myocardial expression of a constitutively active α 1B-adrenergic receptor in transgenic mice induces cardiac hypertrophy. Proc Natl Acad Sci USA 91:10109-10113
47. D'Angelo DD, Sakata Y, Lorenz JN, Boivin GP, Walsh RA, Liggett SB, Dorn II GW 1997 Transgenic Gαq overexpression induces cardiac contractile failure in mice. Proc Natl Acad Sci USA 94:8121-8126
48. LaMorte VJ, Thorburn J, Absher D, Spiegel A, Brown JH, Chien KR, Feramisco JR, Knowlton KU 1994 Gq- and ras-dependent pathways mediate hypertrophy of neonatal rat ventricular myocytes following α1-adrenergic stimulation. J Biol Chem 269:13490-13496
49. Sakata Y, Hoit BD, Liggett SB, Walsh RA, Dorn II GW 1998 Decompensation of pressure-overload hypertrophy in Gαq-overexpressing mice. Circulation 97:1488-1495
50. Adams JW, Pagel AL, Means CK, Oksenberg D, Armstrong RC, Brown JH 2000 Cardiomyocyte apoptosis induced by Gαq signaling is mediated by permeability transition pore formation and activation of the mitochondrial death pathway. Circ Res 87:1180-1187
51. Althoefer H, Eversole-Cire P, Simon MI 1997 Constitutively active Gαq and Gα13 trigger apoptosis through different pathways. J Biol Chem 272:24380-24386
52. Adams JW, Sakata Y, Davis MG, Sah VP, Wang Y, Liggett SB, Chien KR, Brown JH, Dorn II GW 1998 Enhanced Gαq signaling: a common pathway mediates cardiac hypertrophy and apoptotic heart failure. Proc Natl Acad Sci USA 95:10140-10145
53. Adams JW, Brown JH 2001 G-proteins in growth and apoptosis: lessons from the heart. Oncogene 20:1626-1634
54. Douglas SA, Sulpizio AC, Piercy V, Sarau HM, Ames RS, Aiyar NV, Ohlstein EH, Willette RN 2000 Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey. Br J Pharmacol 131:1262-1274
55. Camarda V, Rizzi A, Calo G, Gendron G, Perron SI, Kostenis E, Zamboni P, Mascoli F, Regoli D 2002 Effects of human urotensin Il in isolated vessels of various species; comparison with other vasoactive agents. Naunyn Schmiedebergs Arch Pharmacol 365:141-149
56. Sugden PH 1999 Signaling in myocardial hypertrophy: life after calcineurin? Circ Res 84:633-646
57. Tal M, Ammar DA, Karpuj M, Krizhanovsky V, Naim M, Thompson DA 1995 A novel putative neuropeptide receptor expressed in neural tissue, including sensory epithelia. Biochem Biophys Res Commun 209:752-759
58. Brandenburger Y, Jenkins A, Autelitano DJ, Hannan RD 2001 Increased expression of UBF is a critical determinant for rRNA synthesis and hypertrophic growth of cardiac myocytes. FASEB J 15:2051-2053
59. Swillens S 1992 How to estimate the total receptor concentration when the specific radioactivity of the ligand is unknown. Trends Pharmacol Sci 13:430-434